Symbols

TELA

TELA Bio·NASDAQ

--(--)

TELA fundamentals

TELA Q4 2025 Earnings

TELA Bio (TELA) released its earnings on Mar 24, 2026: revenue was 20.87M (YoY +18.24%), missed estimates; EPS was -0.17 (YoY +26.09%), beat estimates.

Revenue / YoY

20.87M

+18.24%

EPS / YoY

-0.17

+26.09%

Report date

Mar 24, 2026

TELA Earnings Call Summary for Q4,2025

2025 Growth Achievement: 16% full-year revenue growth ($80.3M) driven by U.S. restructuring and European expansion.
2026 Guidance: At least 8% revenue growth (Q1: $18.5M), supported by 88 new reps (40% hired in last 6 months) and product launches.
Key Drivers: OviTex unit growth (22% YoY), LiquiFix tripling, and European sales up 17%.
Risks & Challenges: Q1 impacted by weather and territory changes, with 40% reps in early ramp-up phase.
Strategic Focus: Deeper penetration in high-volume institutions, European PRS expansion, and long-term resorbable OviTex launches.

Earnings

EPS

Revenue

Revenue & Expenses

TELA has released its 2025 Q3 earnings report, with revenue of 20.69M, reflecting a YoY change of 9.14%, and net profit of -8.60M, showing a YoY change of 17.06%. The Sankey diagram below clearly presents TELA's revenue sources and cost distribution.

Key Indicators

TELA Bio (TELA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

TELA Bio (TELA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

TELA Bio (TELA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

TELA Bio (TELA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown